8438 J . Org. Chem., Vol. 63, No. 23, 1998
Feichtinger et al.
Na)+, found 645.3125 ∆ ) 2.0 ppm. Analytical HPLC condi-
tions: 220 nm, 60:40 A/B to 20:80 A/B over 30 min, tR) 27.4
min.
found 873.3019 ∆ ) 3.7 ppm. Analytical HPLC conditions:
220 nm, 70:30 A/B to 10:90 A/B over 30 min, tR ) 16.6 min.
N,N′-Bis(ter t-bu toxyca r bon yl)gu a n id in e (23). 1,4-Di-
oxane (50 mL) was added to a solution of guanidine hydro-
chloride (5, 2.39 g, 25 mmol) and sodium hydroxide (4.0 g, 0.1
mol) in H2O (25 mL), and the resulting mixture was cooled to
0 °C. Di-tert-butyl dicarbonate (12.0 g, 55 mmol) was added
in one portion, and the reaction mixture was allowed to warm
to room temperature within 2 h. After being stirred for 20 h,
the mixture was concentrated in vacuo to one-third of its
original volume. The resulting suspension was diluted with
H2O (50 mL) and extracted with ethyl acetate (3 × 50 mL).
The crude product is a mixture of N-Boc-guanidine, N,N′-bis-
(tert-butoxycarbonyl)guanidine (23), and N,N′,N′′-tri-Boc-
guanidine (1). The combined extracts were washed with 10%
citric acid (N-Boc-guanidine remains in the acidic layer and
may be recovered by cooling the acidic layer in an ice bath,
adjusting the pH to 9.0, and extracting with EtOAc), H2O, and
brine and dried with magnesium sulfate. After filtration and
removal of the solvent under reduced pressure, the crude
product was purified by flash column chromatography on silica
gel (eluent, 100% CH2Cl2 to CH2Cl2/MeOH 97:3). N,N′-Bis-
(tert-butoxycarbonyl)guanidine (23, 3.84 g, 59%) was obtained
as a colorless powder. mp 144-145 °C. 1H NMR (DMSO-d6)
10.42 (br s, 1H), 8.47 (br s, 2H), 1.39 (s, 18H). FABMS m/z
(relative intensity) 260 (50, {M + H}+), 204 (48), 148 (100).
Anal. Calcd for C11H21N3O4: C, 50.95%; H, 8.16%; N, 16.21%.
Found: C, 50.83%; H, 8.04%; N, 16.26%.
N,N′-Bis(ter t-b u t yloxyca r b on yl)-N′′-p en t ylgu a n id in e
(E n t r y 1, Ta b le 1). N,N′-Bis(tert-butyloxycarbonyl)-N′′-
pentylguanidine was prepared according to GPB (solvent )
CH2Cl2, reaction time ) 1 h, rt). mp 73-74 °C. 1H NMR
(DMSO-d6) δ 11.48 (s, 1H), 8.26 (br s, 1H), 3.25 (q, 2H, J )
8.5 Hz), 1.52-1.16 (m, 6H), 1.46 (s, 9H), 1.37 (s, 9H), 0.85 (t,
3H, J ) 8.5 Hz). Anal. Calcd for C16H31N3O4: C, 58.34%; H,
9.49%; N, 12.76%. Found: C, 58.36%; H, 9.60%; N, 13.09%.
Di[N,N′-bis-(ter t-bu tyloxycar bon yl)]piper azin e-1,4-car -
boxa m id in e (En tr y 4, Ta ble 1). Di[N,N′-bis-(tert-butyloxy-
carbonyl)]piperazine-1,4-carboxamidine was prepared accord-
ing to GPB (solvent ) CHCl3, reaction time ) 20 h, rt). 1H
NMR (CDCl3) δ 3.64 (br s, 8H), 1.46 (br s, 36H). Anal. Calcd
for C26H46N6O8: C, 54.72%; H, 8.13%; N, 14.73%. Found: C,
54.59%; H, 7.85%; N, 14.64%.
N ,N ′-B i s -(t er t -b u t y lo x y c a r b o n y l)-N ′′-2-h y d r o x y -
et h ylgu a n id in e (E n t r y 5, Ta b le 1). N,N′-Bis-(tert-butyl-
oxycarbonyl)-N′′-2-hydroxyethylguanidine was prepared ac-
cording to GPB (solvent ) CH2Cl2, reaction time ) 2 h, rt). 1H
NMR (DMSO-d6) δ 11.48 (s, 1H), 8.42 (br s, 1H), 4.88 (t, 1H,
J ) 5.3 Hz), 3.47 (q, 2H, J ) 5.1 Hz), 3.33 (m, 2H), 1.46 (s,
9H), 1.37 (s, 9H). Anal. Calcd for C13H25N3O5: C, 51.48%; H,
8.31%; N, 13.86%. Found: C, 51.23%; H, 8.33%; N, 13.60%.
H-Gly-Ar g-Gly-Asp -Ser -P r o-NH2 (En tr y 1, Ta ble 2).
The hexapeptide Boc-Gly-Orn(Mtt)-Gly-Asp(tBu)-Ser(tBu)-Pro
was assembled on a Rink-amide18 resin (179 mg, 0.1 mmol)
by successive coupling of Fmoc-protected amino acids using
Fastmoc chemistry on an Applied Biosystems automated
peptide synthesizer. After coupling of Boc-Gly-OH in the last
step, the synthesis was completed manually as described
below. The resin was washed with CH2Cl2 (5 × 10 mL) and
with a solution of 1% TFA and 2.5% triisopropylsilane (TIS)
in CH2Cl2 (2 × 10 mL). The Mtt group was removed by
shaking the resin for 2 h in a solution of 1% TFA and 2.5%
TIS in CH2Cl2. The resin was washed with 10% DIEA in
CH2Cl2 (3 × 10 mL) and with CH2Cl2 (5 × 10 mL). The free
amino function was guanidinylated by treatment with a
solution of 3 (180 mg, 0.5 mmol) and triethylamine (70 µL,
0.5 mmol) in CH2Cl2 (2 mL) for 8 h. A negative Kaiser test19
indicated that the reaction had gone to completion. The resin
was washed with CH2Cl2 (5 × 10 mL), methanol, and CH2Cl2
(3 × 10 mL) and dried in vacuo over KOH. The peptide was
cleaved from the resin by treatment with a solution of 2.5%
TIS and 2.5% H2O in TFA for 1 h. The resin was removed by
filtration and washed with TFA (3 × 2 mL). The filtrates were
combined and concentrated under reduced pressure to a small
volume (ca. 0.5 mL). The solution was cooled in an ice bath,
L-N-Boc-ω,ω′-d i-Boc-a r gin in e Meth yl Ester (18). Com-
pound 17 (1.46 g, 2.3 mmol) was dissolved in MeOH (20 mL).
After 10% Pd/C (150 mg) was added, the solution was allowed
to stir under an atmosphere of H2 for 4 h. The product was
filtered over Celite, and the solvent was evaporated to give
an oil, which was precipitated with ether to give 18 as a white
foam (1.05 g, 99%). 1H NMR (CDCl3) δ 11.39 (s, 1H), 8.88 (br
s, 1H), 4.85 (m, 2H), 3.73 (s, 3H), 3.15 (m, 2H), 1.82 (m, 2H),
1.49 (m, 2H), 1.49-1.41 (3 s, 27H). HRFABMS calcd for
C
22H40N4O8 (Mr) 511.2744 (M + Na)+, found 511.2754 ∆ ) 2.0
ppm. Analytical HPLC conditions: 220 nm, 40:60 A/B to 20:
80 A/B over 30 min, tR ) 8.7 min.
N-Meth yl-N,N′,N′′-tr i-Boc-gu a n id in e (19). Compound 19
was prepared according to GPA with the following modifica-
tions: anhydrous methanol (0.04 mL, 1.0 mmol), 1 (539 mg,
1.5 mmol), PPh3 (393 mg, 1.5 mmol), DEAD (0.24 mL, 1.5
mmol). The mixture was allowed to cool to room temperature,
and the solvent was evaporated under reduced pressure. The
crude product was suspended in MeOH (10 mL), and the
precipitate of excess N,N′,N′′-tri-Boc-guanidine that formed
was collected by filtration and washed with MeOH. The
filtrate was concentrated in vacuo, and the product (19) was
isolated as a colorless oil (182 mg, 49%; eluent, CH2Cl2/ethyl
ether 98:2). FABMS m/z (relative intensity) 396 (100, {M +
Na}+), 374 (13, {M + H}+); 1H NMR (DMSO-d6) δ 10.17 (s,
1H), 2.94 (s, 3H), 1.43-1.36 (3 s, 27H). HRFABMS calcd for
C
17H31N3O6 (Mr) 374.2291 (M + H)+, found 374.2298 ∆ ) 1.9
ppm. Analytical HPLC conditions: 220 nm, 50:50 A/B to 5:95
A/B over 30 min, tR ) 14.8 min.
L-N-Cbz-ω-m eth yl-δ,ω,ω′-tr i-Boc-a r gin in e Ben zyl Ester
(20). Compound 20 was prepared according to GPA with the
following modifications: (S)-N-Cbz-2-amino-5-hydroxyvaleric
acid benzyl ester (10, 97 mg, 0.273 mmol), 19 (66 mg, 0.177
mmol), PPh3 (0.11 g, 0.408 mmol), anhydrous THF (3.5 mL),
DEAD (84 µL, 0.408 mmol). The reaction mixture was allowed
to cool to room temperature and the solvent was evaporated
in vacuo. The product (20) was isolated as a colorless oil (113
mg, 87%; eluent, ethyl acetate/hexanes 1:3). 1H NMR (DMSO-
d6) δ 7.80 (d, 1H, J ) 7.9 Hz), 7.39-7.28 (m, 10H), 5.10 (s,
2H), 5.06-4.94 (m, 2H), 4.11-4.00 (m, 1H), 3.53-3.44 (m, 2H),
2.89 (s, 3H), 1.75-1.50 (m, 4H), 1.40-1.34 (3 s, 27H). HR-
FABMS calcd for C37H52N4O10 (Mr) 845.2738 (M + Cs)+, found
845.2709 ∆ ) 3.4 ppm. Analytical HPLC conditions: 220 nm,
30:70 A/B to 10:90 A/B over 30 min, tR ) 12.2 min.
N-P r op yl-N,N′,N′′-tr i-Boc-gu a n id in e (21). Compound 20
was prepared according to GPA with the following modifica-
tions: isopropyl alcohol (0.07 mL, 0.92 mmol), 1 (0.50 g, 1.4
mmol), PPh3 (0.365 g, 1.4 mmol), DEAD (0.22 mL, 1.4 mmol).
The filtrate was concentrated in vacuo, and the product (21)
was isolated as a colorless oil (249 mg, 67%; eluent, EtOAc/
hexanes 1:4). 1H NMR (CDCl3) δ 1.50-1.44 (2 s, 27H), 1.48
(m, 1H, beneath tert-butyl groups), 1.34 (d, 6H, J ) 6.7 Hz).
HRFABMS calcd for C19H35N3O6 (Mr) 402.2604 (M + H)+,
found 402.2613 ∆ ) 2.2 ppm. Analytical HPLC conditions:
220 nm, 50:50 A/B to 5:95 A/B over 30 min, tR ) 18.6 min.
L-N-Cbz-ω-p r op yl-δ,ω,ω′-tr i-Boc-a r gin in e Ben zyl Ester
(22). Compound 22 was prepared according to GPA with the
following modifications. To a solution of PPh3 (0.11 g, 0.402
mmol) and (S)-N-Cbz-2-amino-5-hydroxyvaleric acid benzyl
ester (10, 96.0 mg, 0.268 mmol) in THF (4 mL) was added 21
(0.243 g, 0.604 mmol) via cannulation. After the addition of
DEAD (84 µL, 0.402 mmol) was complete, the reaction mixture
was heated at reflux for 15 h. The mixture was allowed to
cool to room temperature, and the solvent was evaporated
under reduced pressure. The filtrate was concentrated in
vacuo, and the product (22) was isolated as a colorless oil (126
mg, 64%; eluent, EtOAc/hexanes 1:4). 1H NMR (CDCl3) δ
7.36-7.26 (m, 10H), 5.73 (br s, 1H), 5.16 (br s, 2H), 5.09 (br d,
2H, J ) 2.9 Hz), 4.06 (m, 1H), 3.61 (m, 2H), 1.86 (m, 1H), 1.74-
1.68 (m, 4H), 1.45-1.41 (3 s, 27H), 1.23 (d, 6H, J ) 6.5 Hz).
HRFABMS calcd for C39H56N4O10 (Mr) 873.3051 (M + Cs)+,